Abstract
Background
Members of the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing (NLRP) family regulate various physiological and pathological processes. However, none have been shown to regulate actin cap formation or spindle translocation during the asymmetric division of oocyte meiosis I. NLRP4E has been reported as a candidate protein in female fertility, but its function is unknown.
Methods
Immunofluorescence, reverse transcription polymerase chain reaction (RT-PCR), and western blotting were employed to examine the localization and expression levels of NLRP4E and related proteins in mouse oocytes. small interfering RNA (siRNA) and antibody transfection were used to knock down NLRP4E and other proteins. Immunoprecipitation (IP)-mass spectrometry was used to identify the potential proteins interacting with NLRP4E. Coimmunoprecipitation (Co-IP) was used to verify the protein interactions. Wild type (WT) or mutant NLRP4E messenger RNA (mRNA) was injected into oocytes for rescue experiments. In vitro phosphorylation was employed to examine the activation of steroid receptor coactivator (SRC) by NLRP4E.
Results
NLRP4E was more predominant within oocytes compared with other NLRP4 members. NLRP4E knockdown significantly inhibited actin cap formation and spindle translocation toward the cap region, resulting in the failure of polar body extrusion at the end of meiosis I. Mechanistically, GRIN1, and GANO1 activated NLRP4E by phosphorylation at Ser429 and Thr430; p-NLRP4E is translocated and is accumulated in the actin cap region during spindle translocation. Next, we found that p-NLRP4E directly phosphorylated SRC at Tyr418, while p-SRC negatively regulated p-CDC42-S71, an inactive form of CDC42 that promotes actin cap formation and spindle translocation in the GTP-bound form.
Conclusions
NLRP4E activated by GRIN1 and GANO1 regulates actin cap formation and spindle translocation toward the cap region through upregulation of p-SRC-Tyr418 and downregulation of p-CDC42-S71 during meiosis I.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital of Anhui Medical University, Department of Obstetrics and Gynecology, Hefei, China (GRID:grid.412679.f) (ISNI:0000 0004 1771 3402); Tongji University School of Medicine, Reproductive Medicine Center, Shanghai East Hospital, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535); NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X); Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People’s Republic of China, Hefei, China (GRID:grid.419897.a) (ISNI:0000 0004 0369 313X); Nanjing Medical University, State Key Lab of Reproductive Medicine, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
2 The First Affiliated Hospital of Anhui Medical University, Department of Obstetrics and Gynecology, Hefei, China (GRID:grid.412679.f) (ISNI:0000 0004 1771 3402); NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X); Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People’s Republic of China, Hefei, China (GRID:grid.419897.a) (ISNI:0000 0004 0369 313X); Nanjing Medical University, State Key Lab of Reproductive Medicine, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
3 Women’s Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital), Department of Gynecology, Nanjing, China (GRID:grid.459791.7) (ISNI:0000 0004 1757 7869)
4 The First Affiliated Hospital of Anhui Medical University, Department of Obstetrics and Gynecology, Hefei, China (GRID:grid.412679.f) (ISNI:0000 0004 1771 3402); NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X); Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People’s Republic of China, Hefei, China (GRID:grid.419897.a) (ISNI:0000 0004 0369 313X)
5 Tongji University School of Medicine, Reproductive Medicine Center, Shanghai East Hospital, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535)
6 The Third Affiliated Hospital of Zhengzhou University, Center for Reproductive Medicine, Zhengzhou, China (GRID:grid.412719.8)





